Project Grant K08CA286759
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $162K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $399,153 to Alelopharma Inc. to develop an ultra-sensitive molecular diagnostic platform for detecting EML4-ALK gene fusions in non-small cell lung cancer patients. The objective is to create a blood-based "liquid biopsy" test that can accurately identify ALK-positive lesions, which respond well to targeted cancer therapies, without the need for tissue re-biopsy....
- The National Cancer Institute (NCI) awarded a $3,111,184 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research. The grant supports research to investigate the oncogenic mechanisms of the NPM1::TYK2 gene fusion and its role in driving the development of mature T-cell lymphomas, specifically anaplastic large cell lymphoma (ALCL). The project aims to advance the understanding of how this genetic alteration promotes lymphomagenesis...
- This $495,715 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Sloan-Kettering Institute for Cancer Research to decipher the pathogenesis and therapeutic vulnerabilities of acute myeloid leukemia (AML) driven by germline RUNX1 mutations. The project aims to develop faithful preclinical models, including genetically engineered mouse models and patient-derived xenografts, to study the genetic events and disease progression from...
- This $1,138,458 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at the University of Chicago to investigate the role of fungi (mycobiomes) in the development and progression of lung cancer. The project will utilize an innovative 3D-organotypic lung (iLung) model derived from human pluripotent stem cells, along with live spore-based infection methods, to study the direct impact of fungal pathogens like Aspergillus fumigatus on...
- This $292,028 Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate the mechanisms by which oncogene amplification leads to genome instability and the development of therapy-resistant cancer clones. The research will be conducted by the Sloan-Kettering Institute for Cancer Research in New York and is scheduled to run from August 1, 2025 to July 31, 2030. Using single-cell genomic sequencing techniques, the project aims...
- This Project Grant award, totaling $158,365, was provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395). The grant supports research to understand the impact of NRF2 activation on the initiation and progression of lung squamous cell carcinoma (LUSC). The primary awardee, the University of North Carolina at Chapel Hill, will develop a novel genetically-engineered mouse model to test how an activated NRF2 mutation affects LUSC incidence, tumor...
- This $557,418 federal Project Grant was awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) on March 17, 2025 to The Trustees of Columbia University in the City of New York for the project "Targeting SMARCA2 in SMARCA4-Deficient Lung Cancers In Vivo". The project aims to mechanistically evaluate SMARCA2 degradation as a therapeutic approach for treating SMARCA4-deficient lung adenocarcinomas, which account for ~20,000 new lung cancer cases annually in the...
- This Project Grant award of $631,156 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research to uncover the core mechanisms driving lineage plasticity (LP) in EGFR-mutant lung adenocarcinoma (LUAD). The research aims to systematically define the epigenetic, transcriptional, and signaling alterations that facilitate the transformation of LUAD to the more aggressive small cell lung cancer (SCLC) subtype, a lethal mechanism...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $315,246 to New York University School of Medicine to conduct research on breaking cytokine loops in lung adenocarcinoma, the leading subtype of lung cancer. The research aims to define how lung adenocarcinoma tumors with LKB1 mutations interact with the tumor microenvironment, including two specific cytokine signaling loops that promote tumor dedifferentiation and recruit...
- This $150,104 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to understand the evolutionary trajectories of complex genomic rearrangements in cancer. The project aims to develop novel computational approaches, "AGAVE" and "ROSE", to characterize the timing and dynamics of focal amplifications and structural variants during tumor evolution. The research will map these evolutionary patterns across...